Inhibitor Therapeutics (INTI) Interest & Investment Income (2023 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Interest & Investment Income came in at $9207.0 in Q1 2026, down 77.92% YoY from $41705.0 in Q1 2025, and down 53.38% on a QoQ basis from $19749.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Interest & Investment Income (2023 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 4 years of Interest & Investment Income data on file, last reported at $9207.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 77.92% year-over-year to $9207.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93818.0 (down 65.23% YoY) and the FY2025 annual result came in at $126316.0, down 60.3% from the prior year.
- Interest & Investment Income slipped to $9207.0 in Q1 2026, from $19749.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $106008.0 in Q4 2023 to a low of $9207.0 in Q1 2026.
- A 4-year average of $64044.2 and a median of $82239.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income slipped 0.02% — and 2026, when it sank 77.92%.
- Tracing INTI's Interest & Investment Income over 4 years: stood at $106008.0 in 2023, then slumped by 41.13% to $62406.0 in 2024, then sank by 68.35% to $19749.0 in 2025, then slumped by 53.38% to $9207.0 in 2026.
- The last three Interest & Investment Income figures came in at $9207.0 (Q1 2026), $19749.0 (Q4 2025), and $29031.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 4,664.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9,207.00 |
| Dec 31, 2025 | 19,749.00 |
| Sep 30, 2025 | 29,031.00 |
| Jun 30, 2025 | 35,831.00 |
| Mar 31, 2025 | 41,705.00 |
| Dec 31, 2024 | 62,406.00 |
| Sep 30, 2024 | 82,239.00 |
| Jun 30, 2024 | 83,457.00 |
| Mar 31, 2024 | 90,106.00 |
| Dec 31, 2023 | 106,008.00 |
| Sep 30, 2023 | 94,768.00 |
| Jun 30, 2023 | 87,940.00 |
| Mar 31, 2023 | 90,128.00 |